Suppr超能文献

2009年至2013年韩国静脉血栓栓塞症的发病率。

Incidence of venous thromboembolism in Korea from 2009 to 2013.

作者信息

Hong Junshik, Lee Ju Hyun, Yhim Ho-Young, Choi Won-Il, Bang Soo-Mee, Lee Heeyoung, Oh Doyeun

机构信息

Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.

Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.

出版信息

PLoS One. 2018 Jan 25;13(1):e0191897. doi: 10.1371/journal.pone.0191897. eCollection 2018.

Abstract

The incidence of venous thromboembolism (VTE) is lower in Asian populations than in Western populations. The objective of the present study was to evaluate the annual age- and sex-adjusted incidence (ASR) of VTE from 2009 to 2013 in South Korea. In addition, annual change in the pattern of VTE treatment during the study period was estimated because a new direct oral anticoagulant (DOAC) had become available and was covered by health insurance in Korea beginning in January 2013. VTE cases from 2009 to 2013 were retrospectively identified based on both diagnostic and medication codes of anticoagulants used for initial treatment using the Korean Health Insurance Review and Assessment Service (HIRA) databases. The incidence of VTE increased yearly. It was significantly higher in the older population than in the younger population, and it was higher in females than in males. In 2009, ASRs of VTE, deep vein thrombosis, and pulmonary embolism were 21.3, 8.1, and 13.2 cases per 100,000 individuals, respectively in 2009. These increased to 29.2, 12.7, and 16.6 cases per 100,000, respectively, in 2013. Prescription rates of warfarin and low-molecular-weight heparin decreased with the introduction of a new anticoagulant in 2013. The proportion of subjects who underwent mechanical procedures decreased annually. The ASR of VTE in Korea continuously increased from 2009 to 2013, reflecting an increased awareness and detection of VTE as well as improved survival of patients with cancer and other morbidities. Following its introduction, DOAC rapidly replaced other anticoagulants for the treatment of VTE.

摘要

亚洲人群静脉血栓栓塞症(VTE)的发病率低于西方人群。本研究的目的是评估2009年至2013年韩国VTE的年龄和性别调整后的年发病率(ASR)。此外,还估计了研究期间VTE治疗模式的年度变化,因为一种新型直接口服抗凝剂(DOAC)于2013年1月开始在韩国上市并被纳入医疗保险。利用韩国健康保险审查和评估服务(HIRA)数据库,根据用于初始治疗的抗凝剂的诊断和用药代码,回顾性确定了2009年至2013年的VTE病例。VTE的发病率逐年上升。老年人群的发病率明显高于年轻人群,女性高于男性。2009年,VTE、深静脉血栓形成和肺栓塞的ASR分别为每10万人21.3例、8.1例和13.2例。到2013年,这些数字分别增至每10万人29.2例、12.7例和16.6例。2013年引入新型抗凝剂后,华法林和低分子肝素的处方率下降。接受机械手术的受试者比例逐年下降。2009年至2013年,韩国VTE的ASR持续上升,这反映出对VTE的认识和检测有所提高,以及癌症和其他疾病患者的生存率有所改善。DOAC推出后,迅速取代了其他抗凝剂用于VTE的治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5821/5785001/11c904433150/pone.0191897.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验